Have you reviewed your post-Brexit patent and SPC pharma strategies? In a 32-page special report pharma patent specialists Garreth Duncan and Jennifer O'Farrell shine a spotlight on the opportunities and challenges that the pharma industry faces.
Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.
Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies
The extensive and advanced work to develop the critical analytical assays needed for quality control in the manufacture of the AAV1 based gene therapy product CG01 has now been completed in a collaboration between CombiGene and CGT Catapult. CombiGene will now integrate the analytical assays into its production process, taking it another step closer to its final large scale production design for clinical trials and commercial distribution.
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. Eisai join AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the bio-incubator programme
Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.
Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design and manufacturing files of a breathing aid developed by UCL, UCLH and Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP) to support healthcare systems preparing for the Covid-19 pandemic.